Dr Jonathan E. Rosenberg talks to ecancer at ESMO 18 about the CHECKMATE-032 trial looking at nivolumab with ipilimumab for patients with metastatic urothelial carcinoma.
After giving the latest data from the study, Dr Rosenberg provides his opinions and also the future direction for patients with metastatic urothelial carcinoma, given these outcomes.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.
